rs182052 — ADIPOQ ADIPOQ promoter -10066A>G

ADIPOQ -10066A>G — The Quiet Adiponectin Suppressor

Adiponectin is one of the most important hormones your fat tissue produces — it travels to muscle and liver to sharpen insulin sensitivity, dampen inflammation¹¹ inflammation
adiponectin activates AMP-activated protein kinase (AMPK) and suppresses NF-κB inflammatory signalling in macrophages and vascular cells, and reduce triglyceride synthesis. Higher circulating levels predict lower risk of type 2 diabetes, metabolic syndrome, and cardiovascular disease. rs182052 is a variant in the ADIPOQ gene — the gene encoding adiponectin — that quietly suppresses how much of this protective hormone your body makes. Carry one or two copies of the A allele and your adiponectin runs lower than it should for your weight and metabolic state.

The Mechanism

rs182052 sits in an intronic region of ADIPOQ at chromosomal position 3:186,842,993 (GRCh38). The variant is named -10066A>G after its position relative to an older reference point in the promoter region; in current genomic coordinates it lies within the first intron and may influence nearby regulatory elements. Unlike rs17300539 (-11391G>A), a related ADIPOQ promoter SNP where in vitro studies²² in vitro studies
luciferase reporter assays in 3T3-L1 adipocytes showed direct effects on transcriptional activity, promoter assays for rs182052 did not detect significant allelic differences in reporter expression. The effect on serum adiponectin is nonetheless robustly replicated across populations, suggesting the variant influences post-transcriptional regulation, local chromatin structure, or splicing efficiency rather than promoter strength alone.

Each copy of the A allele is associated with progressively lower circulating adiponectin. In the CARDIA study³³ CARDIA study
the Coronary Artery Risk Development in Young Adults cohort, one of the most comprehensive US prospective studies of cardiovascular risk factors, following 5,115 participants since 1985, white participants with GG genotype had a geometric mean adiponectin of 11.1 mg/L, AG carriers 10.2 mg/L, and AA homozygotes 10.1 mg/L — approximately 0.9 mg/L lower per A allele, with a clear dose-response (P=0.0013). A significant interaction with waist circumference suggests the effect is amplified in people carrying more central adiposity.

The Evidence

The association with serum adiponectin is among the most replicated findings for any ADIPOQ variant. Kyriakou et al. (2008)⁴⁴ Kyriakou et al. (2008) analysed two independent cohorts of Caucasian women — the Chingford Study (n=808) and Twins UK (n=2,718) — and found rs182052 significantly associated with fasting adiponectin in both (P as low as 3.19×10⁻⁹). Haplotype analysis showed the SNP contributed 1.66–2.85% of adiponectin variance, a meaningful fraction given adiponectin's tight genetic regulation.

Downstream cardiovascular consequences are documented in the Smetnev et al. (2019) study⁵⁵ Smetnev et al. (2019) study of 447 patients undergoing coronary angiography in Russia. GG carriers had median adiponectin of 8.07 µg/mL versus 7.68 µg/mL in A-allele carriers (P=0.034). Each additional A allele carried an OR of 1.55 (95% CI 1.15–2.09) for coronary artery disease and OR 2.55 (95% CI 1.40–4.82) for unstable angina. The A allele also doubled T2D prevalence (OR 2.29, 95% CI 1.29–4.21).

Zhang et al. (2015)⁶⁶ Zhang et al. (2015) extended the findings to cancer biology in a Chinese case-control study (1,004 RCC patients, 1,108 controls). The A allele reduced adiponectin (β=−0.37 to −0.40, P<0.025) and the AA genotype carried an OR of 1.36 (95% CI 1.07–1.74) for clear cell renal cell carcinoma compared to GG — consistent with adiponectin's established anti-proliferative and anti-angiogenic roles. A meta-analysis of seven studies (n=10,554 subjects)⁷⁷ meta-analysis of seven studies (n=10,554 subjects) confirmed the cancer link across both Asian and Caucasian populations (OR 1.09 per A allele; OR 1.20 for AA vs GG). Joint effects with obesity and arsenic exposure are particularly striking — one study reported OR 9.33 (95% CI 3.85–22.62) for renal cancer in A-allele carriers with combined high arsenic exposure and obesity.

rs182052 has also been linked to knee osteoarthritis risk⁸⁸ knee osteoarthritis risk (OR 1.38 per A allele, P=0.012), consistent with adiponectin's chondroprotective role⁹⁹ chondroprotective role
adiponectin suppresses matrix metalloproteinase expression in chondrocytes and protects cartilage from inflammatory degradation in joint tissue.

Practical Actions

The actionable levers are omega-3 fatty acids and monounsaturated fats, both of which boost adiponectin expression through PPARγ activation. ADIPOQ genotype modifies the response magnitude — A-allele carriers stand to benefit most precisely because their baseline adiponectin runs lower. A direct adiponectin measurement gives you a baseline and tracks whether interventions are working: target above 7 µg/mL; below 4 µg/mL warrants intensified intervention.

Because adiponectin-lowering variants cluster in the ADIPOQ locus, the practical implication of carrying multiple suppressing haplotype alleles (rs182052-A together with rs3774261-G, rs1501299-T, or rs266729-G) is compounded adiponectin suppression that may require more aggressive dietary intervention than any single variant predicts.

Interactions

rs182052 is one of at least five functional ADIPOQ variants. The gene sits at chromosome 3q27, a locus with strong linkage to type 2 diabetes and metabolic syndrome in genome-wide scans. Four other variants in this region are in the GeneOps database: rs17300539 (-11391G>A), rs266729 (-11377C>G), rs2241766 (+45T>G, Gly15Gly), rs1501299 (+276G>T), and rs3774261 (intronic). These variants exist in partial linkage disequilibrium and form haplotypes — the complete haplotype structure often explains more adiponectin variance than any single SNP. Individuals carrying risk alleles at multiple loci may face compounded adiponectin suppression.

There is also evidence for interaction with central obesity: the CARDIA study found the waist circumference × rs182052 interaction was statistically significant, implying the variant's adiponectin-lowering effect is magnified as visceral fat accumulates — a vicious cycle where reduced adiponectin promotes further insulin resistance and fat deposition.